Reproductive immunology in livestock is increasingly shaped by the recognition that fertility depends on a finely tuned balance between immune defense and ...

SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in ...

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

Solid Biosciences (SLDB) stock retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediatric Duchenne ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...

SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex ...

Turn Therapeutics (NASDAQ:TTRX) executives outlined the company’s focus on inflammatory skin disease and provided updates on ...

The firm is hoping to outline a potential path to accelerated approval for SGT-003 as it gears up to launch a randomized, controlled Phase III trial.

By Dr. Liji Thomas, MD As probiotic skincare products claim benefits ranging from anti-aging to mood enhancement, researchers reviewed the scientific evidence and found that while some probiotic ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.15451 EPS, expectations ...

USA: Major Depressive Disorder (MDD), a debilitating psychiatric condition affecting millions worldwide, shares a distinct Type 2 helper T-cell (Th2) immune signature with atopic dermatitis (AD), ...

As of Friday, March 06, Solid Biosciences Inc.’s SLDB share price has surged by 13.19%, which has investors questioning if this is right time to sell.